Abstract C271: FAK inhibitor defactinib (VS-6063) enhances the efficacy of paclitaxel and preferentially targets ovarian cancer stem cells.

Christian M. Vidal; Vihren N. Kolev; Quentin G. Wright; Winnie F. Tam; David T. Weaver; Mahesh V. Padval; Qunli Xu; Jonathan A. Pachter

doi:10.1158/1535-7163.TARG-13-C271

Therapeutic Agents: Small Molecule Kinase Inhibitors

Abstract C271: FAK inhibitor defactinib (VS-6063) enhances the efficacy of paclitaxel and preferentially targets ovarian cancer stem cells.

Christian M. Vidal, Vihren N. Kolev, Quentin G. Wright, Winnie F. Tam, David T. Weaver, Mahesh V. Padval, Qunli Xu and Jonathan A. Pachter

Christian M. Vidal

Verastem, Cambridge, MA

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Vihren N. Kolev

Verastem, Cambridge, MA

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Quentin G. Wright

Verastem, Cambridge, MA

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Winnie F. Tam

Verastem, Cambridge, MA

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

David T. Weaver

Verastem, Cambridge, MA

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Mahesh V. Padval

Verastem, Cambridge, MA

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Qunli Xu

Verastem, Cambridge, MA

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Jonathan A. Pachter

Verastem, Cambridge, MA

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

DOI: 10.1158/1535-7163.TARG-13-C271 Published November 2013

Article
Info & Metrics

Online Impact

Statistics from Altmetric.com

ARTICLE USAGE

ARTICLE USAGE: January 2014 to October 2019

	Abstract	Full-text HTML	PDF
Total	1084	0	70

Cited By

Article Information

Volume 12, Issue 11 Supplement, pp. C271

DOI

https://doi.org/10.1158/1535-7163.TARG-13-C271

Published By

American Association for Cancer Research

Print ISSN

1535-7163

Online ISSN

1538-8514

Author Information

Christian M. Vidal,
Vihren N. Kolev,
Quentin G. Wright,
Winnie F. Tam,
David T. Weaver,
Mahesh V. Padval,
Qunli Xu, and
Jonathan A. Pachter

Verastem, Cambridge, MA

Molecular Cancer Therapeutics: 12 (11 Supplement)

November 2013
Volume 12, Issue 11 Supplement

Table of Contents

Search for this keyword

Article Alerts

User Name *

Password *

Email *

Email Article

Thank you for sharing this Molecular Cancer Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Your Email *

Your Name *

Send To *

Enter multiple addresses on separate lines or separate them with commas.

You are going to email the following Abstract C271: FAK inhibitor defactinib (VS-6063) enhances the efficacy of paclitaxel and preferentially targets ovarian cancer stem cells.

Message Subject (Your Name) has forwarded a page to you from Molecular Cancer Therapeutics

Message Body (Your Name) thought you would be interested in this article in Molecular Cancer Therapeutics.

Your Personal Message

Citation Tools

Abstract C271: FAK inhibitor defactinib (VS-6063) enhances the efficacy of paclitaxel and preferentially targets ovarian cancer stem cells.

Christian M. Vidal, Vihren N. Kolev, Quentin G. Wright, Winnie F. Tam, David T. Weaver, Mahesh V. Padval, Qunli Xu and Jonathan A. Pachter

Mol Cancer Ther November 1 2013 (12) (11 Supplement) C271; DOI: 10.1158/1535-7163.TARG-13-C271

Citation Manager Formats

BibTeX
Bookends
EasyBib
EndNote (tagged)
EndNote 8 (xml)
Medlars
Mendeley
Papers
RefWorks Tagged
Ref Manager
RIS
Zotero

Abstract C271: FAK inhibitor defactinib (VS-6063) enhances the efficacy of paclitaxel and preferentially targets ovarian cancer stem cells.

Christian M. Vidal, Vihren N. Kolev, Quentin G. Wright, Winnie F. Tam, David T. Weaver, Mahesh V. Padval, Qunli Xu and Jonathan A. Pachter

Mol Cancer Ther November 1 2013 (12) (11 Supplement) C271; DOI: 10.1158/1535-7163.TARG-13-C271

Share This Article:

Tweet Widget
Facebook Like
Google Plus One

Jump to section

Article
Info & Metrics

Cited By...

Therapeutic Agents: Small Molecule Kinase Inhibitors

Abstract LB-A20: Novel Dual Oncogenic Target Inhibitor against Allosteric Mitogen-Activated Protein Kinase (MEK1) and Phosphatidylinositol 3-Kinase (PI3K)
Abstract PR13: Clinical safety and activity from a phase 1 study of LOXO-101, a selective TRKA/B/C inhibitor, in solid-tumor patients with NTRK gene fusions
Abstract LB-A21: Single-agent activity and favorable pharmaceutical properties of orally bioavailable next-generation CDK4/6 inhibitor, ON 123300

Show more Therapeutic Agents: Small Molecule Kinase Inhibitors

Therapeutic Agents: Small Molecule Kinase Inhibitors: Poster Presentations - Proffered Abstracts

Abstract LB-A20: Novel Dual Oncogenic Target Inhibitor against Allosteric Mitogen-Activated Protein Kinase (MEK1) and Phosphatidylinositol 3-Kinase (PI3K)
Abstract PR13: Clinical safety and activity from a phase 1 study of LOXO-101, a selective TRKA/B/C inhibitor, in solid-tumor patients with NTRK gene fusions
Abstract LB-A21: Single-agent activity and favorable pharmaceutical properties of orally bioavailable next-generation CDK4/6 inhibitor, ON 123300

Show more Therapeutic Agents: Small Molecule Kinase Inhibitors: Poster Presentations - Proffered Abstracts

Main menu

User menu

Search

Abstract C271: FAK inhibitor defactinib (VS-6063) enhances the efficacy of paclitaxel and preferentially targets ovarian cancer stem cells.

Online Impact

Statistics from Altmetric.com

ARTICLE USAGE

ARTICLE USAGE: January 2014 to October 2019

Cited By

Article Information

Author Information

Citation Manager Formats

Related Articles

Cited By...

More in this TOC Section

Therapeutic Agents: Small Molecule Kinase Inhibitors

Therapeutic Agents: Small Molecule Kinase Inhibitors: Poster Presentations - Proffered Abstracts

Articles

Info for

About MCT